Redeye endorses today’s news that the independent Data and Safety Monitoring Board (DSMB) for the Pirepemat Phase IIb trial “unanimously recommend that the Phase IIb study continues according to the approved study protocol”. While expected, we see this as a confirmation that the trial is progressing as planned. The company reiterates its guidance that top-line data will be presented in H1 2024.